Home Cart Sign in  
Chemical Structure| 195514-63-7 Chemical Structure| 195514-63-7

Structure of Rimiducid
CAS No.: 195514-63-7

Chemical Structure| 195514-63-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Rimiducid (AP1903) is a dimerizer agent that cross-links FKBP domains, dimerizing the Caspase 9 suicide switch to rapidly induce apoptosis.

Synonyms: Ap1903

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Rimiducid

CAS No. :195514-63-7
Formula : C78H98N4O20
M.W : 1411.63
SMILES Code : O=C(N1[C@@H](CCCC1)C(O[C@@H](C2=CC(OCC(NCCNC(COC3=CC([C@@H](CCC4=CC(OC)=C(C=C4)OC)OC([C@H]5N(CCCC5)C([C@H](C6=CC(OC)=C(C(OC)=C6)OC)CC)=O)=O)=CC=C3)=O)=O)=CC=C2)CCC7=CC(OC)=C(C=C7)OC)=O)[C@H](C8=CC(OC)=C(C(OC)=C8)OC)CC
Synonyms :
Ap1903
MDL No. :MFCD25976784
InChI Key :GQLCLPLEEOUJQC-ZTQDTCGGSA-N
Pubchem ID :16135625

Safety of Rimiducid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Rimiducid

PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
T cells 10 nM 24 h Rim-dependent costimulation enhances CAR-T cell proliferation and anti-tumor activity. PMC5589084
Untransduced or CAR transduced T cells 1, 10, or 100 ng/mL 6 h to analyze T cell death PMC7854354
human induced pluripotent stem cells (iPSCs) 10 nM or 50 nM 24 hours To evaluate the killing efficiency of AP1903 on iPSCs, the results showed that AP1903 completely killed iPSCs within 24 hours. PMC7581441
human iPSC-derived mesenchymal stem cells (MSCs) 10 nM 24 hours To evaluate the killing efficiency of AP1903 on iPSC-derived MSCs, the results showed that AP1903 completely killed MSCs within 24 hours. PMC7581441
human iPSC-derived chondrocytes 10 nM 48 hours To evaluate the killing efficiency of AP1903 on iPSC-derived chondrocytes, the results showed that AP1903 killed more than 97% of chondrocytes within 48 hours. PMC7581441
NK cells 1 nM 24 hours To evaluate the effect of iMC expression and activation on NK cell proliferation PMC7218419
THP-1 cells 100 nM 60 minutes To evaluate the activation of NF-κB subunits by iMyD88/CD40, results showed that iMyD88/CD40 induced nuclear translocation of RelA, RelB, and c-Rel subunits. PMC3069772
mouse BM-derived DCs (BMDCs) 100 nM 48 hours To evaluate the activation of BMDCs by iMyD88/CD40, results showed that iMyD88/CD40 significantly upregulated the expression of CD40, CD86, and MHC-II. PMC3069772
human monocyte-derived DCs (MoDCs) 100 nM 48 hours To evaluate the activation of MoDCs by iMyD88/CD40, results showed that iMyD88/CD40 significantly upregulated the expression of CD83 and CD86 and increased IL-12p70 production. PMC3069772

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice HPAC-EGFPluc-bearing mice Intraperitoneal injection 5 mg/kg weekly iMC improves CAR-T cell persistence and efficacy against tumors. PMC5589084
Mice NSG mice intraperitoneal (IP) or intratumOral (IT) injection 2 mg/kg once daily for five consecutive days To evaluate the killing effect of AP1903 on iPSC-derived teratomas, the results showed that AP1903 significantly shrunk or completely eliminated the teratomas. PMC7581441
NOD/SCID/IL-2 gR2/2(NSG) mice THP-1 tumor model Intraperitoneal injection 1 mg/kg weekly for 7 weeks To evaluate the effect of iMC expression and activation on NK cell antitumor activity in vivo PMC7218419
C57BL/6 mice B16.F10 melanoma and EG.7-OVA lymphoma models Intraperitoneal injection 5 mg/kg administered 24 hours post-vaccination, tumor growth was monitored To evaluate the efficacy of iMyD88/CD40-DC vaccine, results showed that iMyD88/CD40-DC significantly inhibited tumor growth and improved survival. PMC3069772

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.71mL

0.14mL

0.07mL

3.54mL

0.71mL

0.35mL

7.08mL

1.42mL

0.71mL

References

 

Historical Records

Categories